United States Nuclear Regulatory Commission - Protecting People and the Environment

Orhan H. Suleiman

Dr. Orhan Suleiman, MS, PhD, FAAPM, FHPS, is a medical physicist and is currently the Senior Science Policy Advisor in the Food and Drug Administration’s (FDA) Office of New Drugs, located in FDA’s Center for Drug Evaluation and Research.  He has previously served in FDA’s Office of Counter-terrorism (2002- 2003), and the Center for Devices and Radiological Health (1977-2002). He currently serves on the NRC’s Advisory Committee on the Medical Use of Isotopes (ACMUI).

Dr. Suleiman has represented the FDA, part of the Department of Health and Human Services, on regulatory and policy issues associated with the manufacturing of the medical isotope technetium-99m, daughter radionuclide of molybdenum-99 (Mo-99). He has been actively involved in the White House global threat reduction initiative to replace weapons grade highly enriched uranium (HEU) with alternative manufacturing processes.  Currently a member of the High Level Group on the Security of Supply of Medical Radioisotopes (HLG-MR), whose objective is to phase out the commercial use of HEU while ensuring an adequate supply of this widely used medical isotope.     

He's served on numerous domestic and international committees, has published over 50 peer reviewed articles, and is a past president of the local Health Physics chapter of the Health Physics Society (HPS).  In addition to the HPS, he has also been active in the American Association of Physicists in Medicine (AAPM), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). His undergraduate degree, along with his MS degree in radiological sciences, are from the U Florida, and his PhD is from Johns Hopkins University.

Page Last Reviewed/Updated Friday, May 23, 2014